Halofuginone
- Level
- Commodity
- Parent
- 51101600
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51101662This classification denotes an angiogenesis activator inhibitor and alkaloid with the molecular formula C16H17BrClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L31MM1385E, chemically known as 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, trans- but generally known as halofuginone, which bears US NIH Compound Identifier 62891. European Medicines Agency schedules Halofuginone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08000MIG. The term HALOFUGINONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). HALOFUGINONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule halofuginone under HS 29335995 and SITC 51576. As of Q4 2014, HALOFUGINONE remains the US FDA Preferred Term for this commodity. Halofuginone bears US NLM identifiers UMLS ID C0062095 and NCI Concept Code C1120. SMILES: BRC1CC2NCN(CC(=O)CC3NCCCC3O)C(=O)C2CC1CL.
Same parent
Under 51101600 · 77Activities that produce or sell this
KBLI · 8Inherited from family 51100000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.